2022
Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection
Chan P, Yoon B, Colby D, Kroon E, Sacdalan C, Sriplienchan S, Pinyakorn S, Ananworanich J, Valcour V, Vasan S, Hsu D, Phanuphak N, Paul R, Spudich S. Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 2022, 76: e718-e726. PMID: 35687498, PMCID: PMC9907536, DOI: 10.1093/cid/ciac466.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsBenzoxazinesCognitionFemaleHeterocyclic Compounds, 3-RingHIV InfectionsHumansMaleRetrospective StudiesConceptsAcute HIV-1 infectionT-cell countsDTG-based antiretroviral therapyAntiretroviral therapyDTG groupEFV groupWeek 96Week 24CD4/CD8 ratioNucleoside reverse transcriptase inhibitorHuman immunodeficiency virus type 1Immunodeficiency virus type 1Fiebig stages IPlasma viral suppressionAcute HIV infectionTreatment-naive individualsHIV-1 infectionPatient Health QuestionnaireReverse transcriptase inhibitorVirus type 1Greater incrementART regimensCD8 ratioViral suppressionHIV infection
2020
Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort
Chan P, Goh O, Kroon E, Colby D, Sacdalan C, Pinyakorn S, Prueksakaew P, Reiss P, Ananworanich J, Valcour V, Spudich S, Paul R. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort. AIDS Research And Therapy 2020, 17: 1. PMID: 31907064, PMCID: PMC6945418, DOI: 10.1186/s12981-019-0257-8.Peer-Reviewed Original ResearchConceptsPatient Health Questionnaire-9Acute HIV infectionWeeks of ARTAntiretroviral therapyPHQ-9 scoresDTG-based antiretroviral therapyLower PHQ-9 scoresDolutegravir-based therapyDTG-based regimenNeuropsychiatric adverse eventsPlasma viral suppressionFirst-line treatmentPre-existing depressionLeast moderate depressionModerate-severe depressionModerate depression symptomsPercentage of participantsDTG useViral suppressionHIV cohortMedian durationAdverse eventsHIV infectionHighest quartileMultivariable analysis
2019
Switch to dolutegravir is well tolerated in Thais with HIV infection
Goh OQ, Colby DJ, Pinyakorn S, Sacdalan C, Kroon E, Chan P, Chomchey N, Kanaprach R, Prueksakaew P, Suttichom D, Trichavaroj R, Spudich S, Robb ML, Phanuphak P, Phanuphak N, Ananworanich J, Group O. Switch to dolutegravir is well tolerated in Thais with HIV infection. Journal Of The International AIDS Society 2019, 22: e25324. PMID: 31294931, PMCID: PMC6621926, DOI: 10.1002/jia2.25324.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCohort StudiesDideoxynucleosidesFemaleHepatitis CHeterocyclic Compounds, 3-RingHIV InfectionsHIV-1HumansMaleMiddle AgedOxazinesPiperazinesPyridonesRisk FactorsThailandYoung AdultConceptsAcute HIV infectionBody mass indexIncident hepatitis C virus infectionHepatitis C virus infectionC virus infectionAdverse eventsAntiretroviral therapyHIV infectionVirus infectionFirst-line antiretroviral therapyHepatitis C virus coinfectionLiver-related adverse eventsLower body mass indexC virus coinfectionDTG-based regimensOnly risk factorMedian body weightPossible adverse eventsHepatitis C virusAbacavir therapyLaboratory abnormalitiesMedian ageVirus coinfectionMass indexNeuropsychiatric symptomsTreatment of Central Nervous System Manifestations of HIV in the Current Era
Handoko R, Spudich S. Treatment of Central Nervous System Manifestations of HIV in the Current Era. Seminars In Neurology 2019, 39: 391-398. PMID: 31378874, DOI: 10.1055/s-0039-1688915.Peer-Reviewed Original ResearchMeSH KeywordsAlkynesAnti-Retroviral AgentsBenzoxazinesCentral Nervous System InfectionsCyclopropanesHeterocyclic Compounds, 3-RingHIV InfectionsHumansOxazinesPiperazinesPyridonesRaltegravir PotassiumConceptsCSF HIVTreatment intensificationCentral nervous system opportunistic infectionsHuman immunodeficiency virus (HIV) infectionCentral nervous system manifestationsCurrent ARV regimenHIV resistance mutationsNeuropsychiatric adverse effectsImmunodeficiency virus infectionNervous system manifestationsNeuropsychiatric side effectsMagnetic resonance imagingCerebrospinal fluid dataSystemic HIVHigh CNS penetrationARV regimenSystem manifestationsOpportunistic infectionsHIV replicationTreatment switchLumbar punctureSleep disturbancesVirus infectionCCR5 inhibitorsNeuropsychiatric impairment